AI assistant
Beta Bionics, Inc. — Director's Dealing 2025
Feb 4, 2025
32351_dirs_2025-02-03_61308554-e016-4b78-8203-52556bab4c42.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Beta Bionics, Inc. (BBNX)
CIK: 0001674632
Period of Report: 2025-01-31
Reporting Person: Russell Steven Jon (N/A)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-01-31 | Employee Stock Option (right to buy) | $7.51 | A | 81217 | Acquired | 2032-12-14 | Common Stock (81217) | Direct |
| 2025-01-31 | Employee Stock Option (right to buy) | $5.10 | A | 53584 | Acquired | 2033-09-13 | Common Stock (53584) | Direct |
| 2025-01-31 | Employee Stock Option (right to buy) | $17 | A | 90637 | Acquired | 2035-01-28 | Common Stock (90637) | Direct |
Footnotes
F1: One-fourth of the shares subject to this option shall vest one year after November 14, 2022, and thereafter 1/36th of the shares subject to this option shall vest on each monthly anniversary thereof.
F2: Immediately prior to the closing of the initial public offering, each share of Class B Common Stock subject to this option was converted into an equal number of shares of Common Stock.
F3: The shares subject to this option shall vest in 48 equal monthly installments measured from September 14, 2023.
F4: Vesting is monthly over a 48-month period starting January 29, 2025 in equal monthly amounts.